Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
Immune checkpoint inhibitors restart and maintain cancer-immunity circulation to normalize the anti-tumor immunity. Currently, anti-PD-1/PD-L1 antibodies, as new milestone in immunotherapy, have significantly improved the prognosis of patients with various malignant tumors. However, anti-PD-1/PD-L1...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2023-09-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1423 |
| _version_ | 1827805083254915072 |
|---|---|
| author | SHAN Baoen |
| author_facet | SHAN Baoen |
| author_sort | SHAN Baoen |
| collection | DOAJ |
| description | Immune checkpoint inhibitors restart and maintain cancer-immunity circulation to normalize the anti-tumor immunity. Currently, anti-PD-1/PD-L1 antibodies, as new milestone in immunotherapy, have significantly improved the prognosis of patients with various malignant tumors. However, anti-PD-1/PD-L1 antibody alone exhibited a low response rate, and the combination of anti-PD-1/PD-L1 antibody with traditional therapies such as surgery, chemotherapy, radiotherapy and targeted therapy have shown great potential. As new immune checkpoint inhibitors or in combination therapy are on the way, tumor immunotherapy is entering the era of post-anti-PD-1/PD-L1 antibody. The methodology of combination therapy and biomarker screening remain the focus. This paper reviews the current status of immune checkpoint inhibitor therapy and makes a perspective for the future of post-anti-PD-1/PD-L1 antibody era. |
| first_indexed | 2024-03-11T21:19:34Z |
| format | Article |
| id | doaj.art-0e878d64cddd4d598607f973387439f1 |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-03-11T21:19:34Z |
| publishDate | 2023-09-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-0e878d64cddd4d598607f973387439f12023-09-28T08:05:29ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782023-09-0150983384110.3971/j.issn.1000-8578.2023.22.14238578.2023.22.1423Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor EraSHAN Baoen0Scientific Research Center of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, ChinaImmune checkpoint inhibitors restart and maintain cancer-immunity circulation to normalize the anti-tumor immunity. Currently, anti-PD-1/PD-L1 antibodies, as new milestone in immunotherapy, have significantly improved the prognosis of patients with various malignant tumors. However, anti-PD-1/PD-L1 antibody alone exhibited a low response rate, and the combination of anti-PD-1/PD-L1 antibody with traditional therapies such as surgery, chemotherapy, radiotherapy and targeted therapy have shown great potential. As new immune checkpoint inhibitors or in combination therapy are on the way, tumor immunotherapy is entering the era of post-anti-PD-1/PD-L1 antibody. The methodology of combination therapy and biomarker screening remain the focus. This paper reviews the current status of immune checkpoint inhibitor therapy and makes a perspective for the future of post-anti-PD-1/PD-L1 antibody era.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1423tumor immunotherapyimmune checkpoint inhibitors therapypd-1/pd-l1 antibody |
| spellingShingle | SHAN Baoen Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era Zhongliu Fangzhi Yanjiu tumor immunotherapy immune checkpoint inhibitors therapy pd-1/pd-l1 antibody |
| title | Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era |
| title_full | Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era |
| title_fullStr | Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era |
| title_full_unstemmed | Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era |
| title_short | Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era |
| title_sort | prospect of tumor treatment in the post pd 1 pd l1 inhibitor era |
| topic | tumor immunotherapy immune checkpoint inhibitors therapy pd-1/pd-l1 antibody |
| url | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1423 |
| work_keys_str_mv | AT shanbaoen prospectoftumortreatmentinthepostpd1pdl1inhibitorera |